specialty medical device News
-
Acumed Acquires Exsomed to Enhance Its Portfolio of Upper Extremity Solutions
Acumed, a Colson Medical - Marmon - Berkshire Hathaway company, is excited to announce the acquisition of ExsoMed, a provider of innovative solutions for hand surgery. The addition of ExsoMed, whose products support an intramedullary approach to treating hand fractures, enhances Acumed’s comprehensive portfolio of upper extremity solutions for simple to complex injuries. Acumed, a Colson ...
-
Aurora BioPharma to Attend the Oppenheimer & Co. 27th Annual Healthcare Conference at the Westin New York Grand Central in New York City
Aurora BioPharma, Inc., a clinical stage biotechnology company developing CAR T Cell Therapy to treat Solid and Liquid tumors, announced today that company CEO and President, Robert Brooks, will attend the Oppenheimer & Co. 27th Annual Healthcare Conference on March 21-22, 2017 at The Westin New York Grand Central in New York City. The event is one of the most important investor conferences ...
-
Lynn L. Bergeson Will Speak on REACH at the CSPA International Affairs Conference
Washington D.C. -- Bergeson & Campbell, P.C. (B&C), The Acta Group, L.L.C. (Acta), and The Acta Group EU, Ltd (Acta EU) are pleased to announce that Lynn L. Bergeson will speak, Saturday, December 4, 2010, about Toxic Substances Control Act (TSCA) reform legislation and the role of the European Union's (EU) Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) ...
By Acta Group
-
Lynn L. Bergeson will speak on REACH at the CSPA international affairs conference
Bergeson & Campbell, P.C. (B&C), The Acta Group, L.L.C. (Acta), and The Acta Group EU, Ltd (Acta EU) are pleased to announce that Lynn L. Bergeson will speak, Saturday, December 4, 2010, about Toxic Substances Control Act (TSCA) reform legislation and the role of the European Union's (EU) Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) program at the Seventh ...
By Acta Group
-
Lynn L. Bergeson Will Speak on REACH at the CSPA International Affairs Conference
Washington D.C. -- Bergeson & Campbell, P.C. (B&C), The Acta Group, L.L.C. (Acta), and The Acta Group EU, Ltd (Acta EU) are pleased to announce that Lynn L. Bergeson will speak, Saturday, December 4, 2010, about Toxic Substances Control Act (TSCA) reform legislation and the role of the European Union's (EU) Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) ...
-
JenaValve Technology Closes $50 Million Financing
JenaValve Technology, Inc., developer and manufacturer of the JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of aortic valve disease, announces that it has raised $50 million in an equity financing led by Bain Capital Life Sciences. Additional participants in the financing included existing investors Andera Partners, Gimv, Legend Capital, NeoMed ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you